Vitamin D modulates biliary fibrosis in ABCB4-deficient mice
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
PURPOSE: Impaired vitamin D receptor signaling represents an aggravating factor during liver injury, and recent studies suggest that vitamin D might exert a protective role in chronic hepatobiliary diseases. We hypothesized that vitamin D supplementation would ameliorate liver fibrosis in ATP-binding cassette transporter B4 knockout (Abcb4 (-/-)) mice as a preclinical model of sclerosing cholangitis. METHODS: Abcb4 (-/-) and wild-type mice were fed a regular chow diet (600 IU vitamin D/kg food) or diets with lower (100 IU/kg) and higher (2,400 IU/kg) vitamin D concentrations for 12 weeks. Serum 25-hydroxyvitamin D concentrations were measured by chemiluminescence immunoassays. Liver injury and biliary fibrosis were assessed by liver enzyme activities, histopathology and hepatic collagen contents. Hepatic mRNA expression of markers for fibrosis, vitamin D and bile acid metabolism were analyzed by quantitative PCR. RESULTS: Different vitamin D concentrations were observed depending on genotype and diet group, with Abcb4 (-/-) mice on the control diet showing lower vitamin D concentrations compared to wild-type mice. Abcb4 (-/-) animals on the low vitamin D diet demonstrated the most advanced liver fibrosis and highest hepatic collagen contents. Feeding Abcb4 (-/-) mice a high vitamin D diet enriched serum vitamin D levels, lowered liver enzyme activities, altered expression levels of profibrogenic genes and ameliorated, in part, liver injury. CONCLUSIONS: This is the first report to demonstrate that fibrogenesis in the established Abcb4 (-/-) model is influenced by vitamin D supplementation. Since vitamin D modulates sclerosing cholangitis in vivo, we speculate that sufficient vitamin D intake might improve liver damage and induce antifibrotic effects in chronic cholestasis in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Results from other studies further support the protective role of Vitamin D and VDR activation against hepatic fibrosis, evidenced by a reduction of hydroxyproline levels and decreased expression levels of pro-fibrogenic genes (e.g., col1α1 and tissue inhibitor of metalloproteinase-1 (TIMP-1)) in Mdr2 -/-mice after supplementation of Vitamin D. [98]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029 · cited 1×
“Hepatic fibrosis was staged (F-score) using a scale adapted from the Batts and Ludwig as well as Ishak scoring systems [22, 23].”
MethodBataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Vitamin D Receptor As an Intestinal Bile Acid Sensor
Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., & Mangelsdorf, D. J. (2002) · Science · doi:10.1126/science.1070477 · Cited by 1,176
Gombart, A. F., Borregaard, N., & Koeffler, H. P. (2005) · The FASEB Journal · doi:10.1096/fj.04-3284com · Cited by 1,136
An Update on Terminology and Reporting
Batts, K. P., & Ludwig, J. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199512000-00007 · Cited by 1,080 · cited 1×
“Hepatic fibrosis was staged (F-score) using a scale adapted from the Batts and Ludwig as well as Ishak scoring systems [22, 23].”
MethodPálmer, H. G., González-Sancho, J. M., Espada, J., Berciano, M. T., Puig, I., Baulida, J., Quintanilla, M., Cano, A., de Herreros, A. G., Lafarga, M., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200102028 · Cited by 802
Bile acids as regulatory molecules
Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., & Dent, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900007-jlr200 · Cited by 694 · cited 1×
“VDR, FXR and PXR [35–38].”
Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier
Kong, J., Zhang, Z., Musch, M. W., Ning, G., Sun, J., Hart, J., Bissonnette, M., & Li, Y. C. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00398.2007 · Cited by 667 · cited 1×
“Since vitamin D has been shown to be involved in the regulation of apical junctional complexes in other organs [43–45], Firrincieli et al.”
Research works printed but not linked: 1
- National Research Council. Nutrient Requirements of Laboratory Animals, Fourth Revised Edition, Washington, DC: The National Academies Press; 1995. 80–102
Cited by
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
“The anti-fibrotic potential of VDR stimulation has been demonstrated in several models of liver fibrosis, among them the Mdr2 (Abcb4) / mice [192,193].”
BackgroundPrimary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults
Stättermayer, A. F., Halilbasic, E., Wrba, F., Ferenci, P., & Trauner, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.036 · Cited by 113
The role of vitamin D and vitamin D binding protein in chronic liver diseases
Pop, T. L., Sîrbe, C., Benţa, G., Mititelu, A., & Grama, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810705 · Cited by 105
“Vitamin D administration reduces extracellular matrix deposition and attenuates fibrosis in animal models of chronic hepatic injury [16,54,59], but the ability to remediate already-established fibrosis is less promising.”
BackgroundJaved, Z., Papageorgiou, M., Deshmukh, H., Kilpatrick, E. S., Mann, V., Corless, L., Abouda, G., Rigby, A. S., Atkin, S. L., & Sathyapalan, T. (2019) · Nutrients · doi:10.3390/nu11010188 · Cited by 99
Bellan, M., Andréoli, L., Mele, C., Sainaghi, P. P., Rigamonti, C., Piantoni, S., Benedittis, C. D., Aimaretti, G., Pirisi, M., & Marzullo, P. (2020) · Nutrients · doi:10.3390/nu12030789 · Cited by 81
“Supplementation of vitamin D may prevent liver fibrosis development, as resulted in murine models of primary sclerosing cholangitis [265] and thioacetamide-induced cirrhosis [259].”
BackgroundVitamin D in liver disease: Current evidence and potential directions
Elangovan, H., Chahal, S., & Gunton, J. E. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.01.001 · Cited by 65
Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis
Czaja, A. J., & Montaño‐Loza, A. J. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5351-6 · Cited by 63
Animal models of cholestasis: An update on inflammatory cholangiopathies
Mariotti, V., Cadamuro, M., Spirli, C., Fiorotto, R., Strazzabosco, M., & Fabris, L. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.025 · Cited by 56
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Reiter, F. P., Hohenester, S. D., Nagel, J. M., Wimmer, R., Artmann, R., Wottke, L., Makeschin, M., Mayr, D. C., Rust, C., Trauner, M., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.074 · Cited by 46
Nuclear Receptors in Acute and Chronic Cholestasis
Gonzalez‐Sanchez, E., Firrincieli, D., Housset, C., & Chignard, N. (2015) · Digestive Diseases · doi:10.1159/000371688 · Cited by 39
Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow
Halilbasic, E., Fuchs, C. D., Hofer, H., Paumgartner, G., & Trauner, M. (2015) · Digestive Diseases · doi:10.1159/000440827 · Cited by 36
Targeting Hepatic Fibrosis in Autoimmune Hepatitis
Montaño‐Loza, A. J., Thandassery, R. B., & Czaja, A. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4254-7 · Cited by 32
Gonzalez‐Sanchez, E., Firrincieli, D., Housset, C., & Chignard, N. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.04.004 · Cited by 33
“Because Vdr is involved in innate immunity [10] and has anti-inflammatory and anti-fibrotic effects [12-14, 45], our results reinforce the interest for Vdr as a therapeutic target in chronic cholestatic liver diseases.”
BackgroundResultBile Acids—A Peek Into Their History and Signaling
Nguyen, J. T., Shaw, R. P. H., & Anakk, S. (2022) · Endocrinology · doi:10.1210/endocr/bqac155 · Cited by 24
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
“fibrosis.[218] In addition, hepatic biliary injury is exaggerated in vitamin D receptor (VDR)-knockout mice,[219] suggesting”
BackgroundVitamin D in Preclinical Models of Fatty Liver Disease
Karataylı, E., Stokes, C. S., & Lammert, F. (2019) · Anticancer Research · doi:10.21873/anticanres.13981 · Cited by 20
Self-citationKempińska‐Podhorodecka, A., Milkiewicz, M., Jabłoński, D., Milkiewicz, P., & Wunsch, E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176264 · Cited by 17
Zhuang, P., Sun, S., Dong, R., Chen, G., Huang, Y., & Zheng, S. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/4621372 · Cited by 14
“The administration of VD can significantly reduce deposition of extracellular matrix (ECM) and attenuate the fibrotic score in different animal models of hepatic injury [26, 28, 29].”
BackgroundGonzalez‐Sanchez, E., Mourabit, H. E., Jäger, M., Clavel, M.-A. A., Moog, S., Vaquero, J., Ledent, T., Cadoret, A., Gautheron, J., Fouassier, L., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166067 · Cited by 12
“Yet, Abcb4 knockout mice on low vitamin D diet display aggravated liver fibrosis, which in this particular case, can be ameliorated by a vitamin D-sufficient diet [6].”
BackgroundInfluentialVitamin D in liver cancer: novel insights and future perspectives
Markotić, A., Kelava, T., Markotić, H., Silovski, H., & Mrzljak, A. (2022) · Croatian Medical Journal · doi:10.3325/cmj.2022.63.187 · Cited by 13
Gao, F., Guan, C., Cheng, N., Liu, Y., Wu, Y., Shi, B., Huang, J., Li, S., Tong, Y., Gao, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117250 · Cited by 10
Rastegar-Moghaddam, S. H., Akbarian, M., Rajabian, A., Alipour, F., Ebrahimzadeh‐Bideskan, A., & Hosseini, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18860 · Cited by 11
Antifibrotic Effects of 1,25(OH)2D3 on Nonalcoholic Steatohepatitis in Female Mice
Ma, L., Ishigami, M., Honda, T., Yokoyama, S., Yamamoto, K., Ishizu, Y., Kuzuya, T., Hayashi, K., Hirooka, Y., & Goto, H. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05560-3 · Cited by 9
Cartes‐Velásquez, R., Vera, A., Torres-Quevedo, R., Medrano‐Díaz, J., Pérez, A. J., Muñoz, C., Carrillo-Bestagno, H., & Nova‐Lamperti, E. (2024) · Nutrients · doi:10.3390/nu16234134 · Cited by 8
Ambrosini, Y. M., Piedra-Mora, C., Jennings, S., & Webster, C. R. L. (2022) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16424 · Cited by 7
“In laboratory rodents, VD deficiency results in development of endstage fibrotic liver disease.(22-24) Moreover, VD supplementation in humans and laboratory rodents with CH has anti-inflammatory and antifibrotic effects.”
BackgroundMethodMolecular mechanisms of transporter regulation and their impairment in intrahepatic cholestasis
Li, X., Zu, Y. X., Li, G., Xiang, D., Zhang, C., & Liu, D. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0029 · Cited by 6
Serum vitamin D status in sick cats with and without cholestatic liver disease
Kibler, L. N., Heinze, C. R., & Webster, C. R. L. (2020) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x19895081 · Cited by 7
Golonka, R. M., Yeoh, B. S., Li, Y., Saha, P., Abokor, A. A., Cheng, X., Xiao, X., Chandrashekar, D. S., Varambally, S., Gonzalez, D. J., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00349.2019 · Cited by 6
Mouse models of primary sclerosing cholangitis: we just can’t get enough
Arechederra, M., Fernández‐Barrena, M. G., Berasain, C., & Avila, M. A. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.106 · Cited by 3
Bai, Z., Wang, Y., Li, Y., Xu, J., & Lai, Z. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1684303 · Cited by 2
Weber, S. N., Nowak, I., Grünhage, F., & Lammert, F. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101077 · Cited by 2
Self-citationVitamin D3 and Liver Protection
Al-Saadi, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00021-5
The Role of 1,25(OH)2D3 on GCDC-Induced Apoptosis in HiBECs by Stabilising Mitochondrial DNA
李, 永. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441290
Yang, J., Xu, T., & Xu, R. (2026) · Histochemistry and Cell Biology · doi:10.1007/s00418-026-02462-0
Metadata
- Authors
- Hochrath, K., Stokes, C. S., Geisel, J., Pollheimer, M. J., Fickert, P., Dooley, S., & Lammert, F.
- Affiliations
- Saarland University (DE)
- Universitätsklinikum des Saarlandes (DE)
- Medical University of Graz (AT)
- Heidelberg University (DE)
- Corresponding author
- Lammert, Frank
- Venue
- Hepatology International
- Published
- 2014-06-21
- Volume
- 8
- Issue
- 3
- Pages
- 443-452
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- PMC
- PMC4148166
- OpenAlex
- W2011489820
- Cited by
- 36
- References
- 46
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Hepatology International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB‐TRR57, SFB/TRR57 TP01, DFG: SFB/TRR57)
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
- Keywords
- vitamin D, biliary fibrosis, sclerosing cholangitis, ABCB4, Abcb4 knockout mice, vitamin D receptor signaling, liver fibrosis, chronic cholestasis, bile acid metabolism, hepatic collagen, vitamin D supplementation, antifibrotic effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.